DNLI
DNLI
NASDAQ · Biotechnology

Denali Therapeutics Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks
$19.62
-0.09 (-0.46%)
As of May 9, 1:24 AM ET ·
Analyst Consensus
Strong Buy
25
Analysts
High
Coverage
Buy 23 92%
Hold 2 8%
Sell 0 0%
Price Target
Analyst Price Target +290.2% upside
Low Target $56.04
Average Target $76.55
High Target $105.76
Current Price $19.62
Current
$19.62
Target
$76.55
$56.04 $76.55 avg $105.76
Scenario Analysis
Bear Case
$56.04
185.6%
Low target
Base Case
$76.55
+290.2%
Avg target
Bull Case
$105.76
+439.0%
High target
Risk/Reward
2.4x
Favorable
Price in Context
52-Week High
$23.77
-17.5% from high
52-Week Low
$12.58
+56.0% from low
50-Day SMA
$18.67
+5.1% vs SMA
200-Day SMA
$15.96
+22.9% vs SMA
RSI (14)
42.3
Neutral
Target vs 52W High
$76.55
+222.0% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
 Buy 39 72% $257.58 +27.8%
AMGN
Amgen Inc
 Hold 43 49% $190.87 -42.5%
GILD
Gilead Sciences Inc
 Strong Buy 39 79% $362.68 +176.2%
VRTX
Vertex Pharmaceuticals Inc
 Strong Buy 39 79% $438.34 +2.0%
REGN
Regeneron Pharmaceuticals
 Strong Buy 38 79% $76.80 -89.3%
ALNY
Alnylam Pharmaceuticals Inc
 Strong Buy 36 75% $102.31 -65.3%
RVMD
Revolution Medicines Inc
 Strong Buy 27 96% $114.11 -19.5%
INSM
Insmed Inc
 Strong Buy 26 96% $143.40 +41.5%